“An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s73, doi:10.25251/skin.4.supp.73.